Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.45 - $6.72
Previous CloseN/A
Volume51.94M
Average Volume (3M)5.95M
Market Cap
$375.58M
Enterprise Value$303.13M
Total Cash (Recent Filing)-$13.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Mar 18, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding114,855,760
10 Day Avg. Volume5,092,963
30 Day Avg. Volume5,948,307
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)93.37
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit53.01
Enterprise Value/Ebitda-3.63
Forecast
1Y Price Target
$8.60Price Target Upside163.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbsci has shown significant revenue growth, with a 34% quarter-over-quarter increase and a 129% year-over-year increase, primarily driven by payments for partnered programs.
Partnerships And CollaborationsAbsci's partnerships with major pharmaceutical companies such as Merck, Almirall, and AstraZeneca have the potential to generate over $1.5B in revenue, highlighting the company's strong industry connections.
Bears Say
Competition And DifferentiationDifferentiation is challenging in the AI/ML space due to ongoing expansion and clinical proof of concept being several years away.
---
Ownership Overview
27.71% Insiders
20.36% Mutual Funds
27.57% Other Institutional Investors
8.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.45 and its highest was $6.72 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $375.58M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Mar 18, 2025 which is in 12 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Nov 12, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.194 by -$0.046.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.22.
How many shares outstanding does AbSci have?
AbSci has 114,855,760 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.194. Following the earnings report the stock price went down -14.953%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.60 (163.00% Upside)
$8.60 (163.00% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.03%
12-Months-Change
Fundamentals
Return on Equity
-48.51%
Trailing 12-Months
Asset Growth
-0.47%
Trailing 12-Months
Company Description
AbSci
AbSci (ABSI) is a biotechnology company specializing in protein-based drug discovery and development. The company leverages its proprietary platform, SoluPro, which utilizes synthetic biology to facilitate the efficient production of complex biologics. AbSci focuses on advancing therapeutic programs through partnerships with pharmaceutical companies, aiming to enhance the discovery, development, and manufacturing of protein-based therapeutics.
---
ABSI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, such as collaborations with AstraZeneca and Twist Bioscience, financial stability, and upcoming strategic events. However, it also noted increased R&D expenses, a delay in the ABS-301 program, and modest revenue figures. The positive elements slightly outweigh the negative aspects.Read More>---
ABSI Stock 12 Month Forecast
Average Price Target
$8.60
▲(163.00% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Twist Bioscience
―
Ginkgo Bioworks Holdings
―
Best Analysts Covering ABSI
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+58.07%
reiterated a buy rating last month
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +58.07% per trade.
---